Does the media prefer NRIX or KYMR?

In the previous week, Kymera Therapeutics had 2 more articles in the media than Nurix Therapeutics. MarketBeat recorded 10 mentions for Kymera Therapeutics and 8 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 0.82 beat Kymera Therapeutics' score of 0.75 indicating that Nurix Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PRAX or NRIX?

In the previous week, Praxis Precision Medicines had 8 more articles in the media than Nurix Therapeutics. MarketBeat recorded 16 mentions for Praxis Precision Medicines and 8 mentions for Nurix Therapeutics. Praxis Precision Medicines' average media sentiment score of 1.20 beat Nurix Therapeutics' score of 0.82 indicating that Praxis Precision Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 10 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nurix Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NRIX or SYRE?

In the previous week, Spyre Therapeutics had 4 more articles in the media than Nurix Therapeutics. MarketBeat recorded 12 mentions for Spyre Therapeutics and 8 mentions for Nurix Therapeutics. Spyre Therapeutics' average media sentiment score of 0.83 beat Nurix Therapeutics' score of 0.82 indicating that Spyre Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spyre Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CRNX or NRIX?

In the previous week, Crinetics Pharmaceuticals had 4 more articles in the media than Nurix Therapeutics. MarketBeat recorded 12 mentions for Crinetics Pharmaceuticals and 8 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 0.82 beat Crinetics Pharmaceuticals' score of 0.68 indicating that Nurix Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crinetics Pharmaceuticals 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Nurix Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PTGX or NRIX?

In the previous week, Protagonist Therapeutics had 5 more articles in the media than Nurix Therapeutics. MarketBeat recorded 13 mentions for Protagonist Therapeutics and 8 mentions for Nurix Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.58 beat Nurix Therapeutics' score of 0.82 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 12 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Nurix Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Nurix Therapeutics (NRIX) Competitors

$23.21 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$23.52 +0.31 (+1.32%)

As of 07/31/2026 07:56 PM Eastern

Compare

NRIX vs. KYMR, PRAX, SYRE, CRNX, and PTGX

Should you buy Nurix Therapeutics stock or one of its competitors? MarketBeat compares Nurix Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nurix Therapeutics include Kymera Therapeutics (KYMR), Praxis Precision Medicines (PRAX), Spyre Therapeutics (SYRE), Crinetics Pharmaceuticals (CRNX), and Protagonist Therapeutics (PTGX).

How does Nurix Therapeutics compare to Kymera Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and Kymera Therapeutics (NASDAQ:KYMR) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Nurix Therapeutics presently has a consensus price target of $34.00, indicating a potential upside of 46.49%. Kymera Therapeutics has a consensus price target of $124.48, indicating a potential upside of 20.39%. Given Nurix Therapeutics' higher possible upside, equities analysts clearly believe Nurix Therapeutics is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

Kymera Therapeutics has a net margin of -611.94% compared to Nurix Therapeutics' net margin of -928.44%. Kymera Therapeutics' return on equity of -24.71% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-928.44%	-76.09%	-57.31%
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

Nurix Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 1.95, suggesting that its share price is 95% more volatile than the broader market.

Nurix Therapeutics has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$36.77M	65.52	-$264.46M	-$3.45	N/A
Kymera Therapeutics	$51.48M	165.23	-$311.35M	-$3.57	N/A

In the previous week, Kymera Therapeutics had 2 more articles in the media than Nurix Therapeutics. MarketBeat recorded 10 mentions for Kymera Therapeutics and 8 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 0.82 beat Kymera Therapeutics' score of 0.75 indicating that Nurix Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kymera Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Kymera Therapeutics beats Nurix Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Nurix Therapeutics compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Nurix Therapeutics (NASDAQ:NRIX) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

Praxis Precision Medicines has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -928.44%. Praxis Precision Medicines' return on equity of -43.02% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-43.02%	-40.22%
Nurix Therapeutics	-928.44%	-76.09%	-57.31%

Praxis Precision Medicines has a beta of 2.74, suggesting that its share price is 174% more volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the broader market.

In the previous week, Praxis Precision Medicines had 8 more articles in the media than Nurix Therapeutics. MarketBeat recorded 16 mentions for Praxis Precision Medicines and 8 mentions for Nurix Therapeutics. Praxis Precision Medicines' average media sentiment score of 1.20 beat Nurix Therapeutics' score of 0.82 indicating that Praxis Precision Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	10 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nurix Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

67.8% of Praxis Precision Medicines shares are owned by institutional investors. 3.0% of Praxis Precision Medicines shares are owned by company insiders. Comparatively, 6.7% of Nurix Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Nurix Therapeutics has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	N/A	N/A	-$303.27M	-$13.37	N/A
Nurix Therapeutics	$36.77M	65.52	-$264.46M	-$3.45	N/A

Praxis Precision Medicines currently has a consensus price target of $563.50, suggesting a potential upside of 83.06%. Nurix Therapeutics has a consensus price target of $34.00, suggesting a potential upside of 46.49%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, research analysts plainly believe Praxis Precision Medicines is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	4 Strong Buy rating(s)	2.95
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Praxis Precision Medicines beats Nurix Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Nurix Therapeutics compare to Spyre Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and Spyre Therapeutics (NASDAQ:SYRE) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

80.4% of Spyre Therapeutics shares are owned by institutional investors. 6.7% of Nurix Therapeutics shares are owned by company insiders. Comparatively, 15.7% of Spyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Spyre Therapeutics has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -928.44%. Spyre Therapeutics' return on equity of -42.88% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-928.44%	-76.09%	-57.31%
Spyre Therapeutics	N/A	-42.88%	-27.76%

Spyre Therapeutics has lower revenue, but higher earnings than Nurix Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$36.77M	65.52	-$264.46M	-$3.45	N/A
Spyre Therapeutics	N/A	N/A	-$155.20M	-$2.08	N/A

In the previous week, Spyre Therapeutics had 4 more articles in the media than Nurix Therapeutics. MarketBeat recorded 12 mentions for Spyre Therapeutics and 8 mentions for Nurix Therapeutics. Spyre Therapeutics' average media sentiment score of 0.83 beat Nurix Therapeutics' score of 0.82 indicating that Spyre Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spyre Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Nurix Therapeutics presently has a consensus target price of $34.00, indicating a potential upside of 46.49%. Spyre Therapeutics has a consensus target price of $101.42, indicating a potential upside of 3.14%. Given Nurix Therapeutics' higher possible upside, equities analysts plainly believe Nurix Therapeutics is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Nurix Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.02, indicating that its stock price is 202% more volatile than the broader market.

Summary

Spyre Therapeutics beats Nurix Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Nurix Therapeutics compare to Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Nurix Therapeutics (NASDAQ:NRIX) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

Nurix Therapeutics has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$18.07M	487.37	-$465.32M	-$5.13	N/A
Nurix Therapeutics	$36.77M	65.52	-$264.46M	-$3.45	N/A

Nurix Therapeutics has a net margin of -928.44% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. Crinetics Pharmaceuticals' return on equity of -43.96% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%
Nurix Therapeutics	-928.44%	-76.09%	-57.31%

Crinetics Pharmaceuticals presently has a consensus target price of $81.00, indicating a potential downside of 3.02%. Nurix Therapeutics has a consensus target price of $34.00, indicating a potential upside of 46.49%. Given Nurix Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Nurix Therapeutics is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Comparatively, 6.7% of Nurix Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Crinetics Pharmaceuticals had 4 more articles in the media than Nurix Therapeutics. MarketBeat recorded 12 mentions for Crinetics Pharmaceuticals and 8 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 0.82 beat Crinetics Pharmaceuticals' score of 0.68 indicating that Nurix Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crinetics Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Nurix Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Crinetics Pharmaceuticals has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market.

Summary

Nurix Therapeutics beats Crinetics Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Nurix Therapeutics compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Nurix Therapeutics (NASDAQ:NRIX) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

Protagonist Therapeutics presently has a consensus price target of $123.00, suggesting a potential downside of 9.98%. Nurix Therapeutics has a consensus price target of $34.00, suggesting a potential upside of 46.49%. Given Nurix Therapeutics' higher possible upside, analysts clearly believe Nurix Therapeutics is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Protagonist Therapeutics has a net margin of -154.88% compared to Nurix Therapeutics' net margin of -928.44%. Protagonist Therapeutics' return on equity of -17.76% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Nurix Therapeutics	-928.44%	-76.09%	-57.31%

In the previous week, Protagonist Therapeutics had 5 more articles in the media than Nurix Therapeutics. MarketBeat recorded 13 mentions for Protagonist Therapeutics and 8 mentions for Nurix Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.58 beat Nurix Therapeutics' score of 0.82 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	12 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Nurix Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Protagonist Therapeutics has higher revenue and earnings than Nurix Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$74.06M	118.65	-$130.15M	-$1.81	N/A
Nurix Therapeutics	$36.77M	65.52	-$264.46M	-$3.45	N/A

98.6% of Protagonist Therapeutics shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by company insiders. Comparatively, 6.7% of Nurix Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Protagonist Therapeutics has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market.

Summary

Protagonist Therapeutics beats Nurix Therapeutics on 12 of the 16 factors compared between the two stocks.

Get Nurix Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NRIX vs. The Competition

Export

Metric	Nurix Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.41B	$3.54B	$6.85B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-6.73	7.38	282.28	24.66
Price / Sales	65.52	1,199.83	563.21	75.35
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	4.39	16.96	10.96	6.07
Net Income	-$264.46M	-$12.56M	$3.49B	$347.99M
7 Day Performance	-0.94%	-1.80%	-0.63%	-0.44%
1 Month Performance	-3.21%	-8.44%	-5.23%	-4.81%
1 Year Performance	110.24%	48.63%	62.07%	18.61%

Nurix Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NRIX Nurix Therapeutics	2.6619 of 5 stars	$23.21 flat	$34.00 +46.5%	+110.2%	$2.41B	$36.77M	N/A	300
KYMR Kymera Therapeutics	2.1632 of 5 stars	$110.05 -0.5%	$122.64 +11.4%	+140.7%	$9.10B	$51.48M	N/A	170	Upcoming Earnings Gap Up
PRAX Praxis Precision Medicines	4.0016 of 5 stars	$315.80 -2.9%	$563.50 +78.4%	+469.1%	$9.07B	N/A	N/A	110	Positive News Upcoming Earnings
SYRE Spyre Therapeutics	2.3147 of 5 stars	$100.04 -2.0%	$101.42 +1.4%	+504.7%	$8.98B	N/A	N/A	73	News Coverage Upcoming Earnings Gap Up
CRNX Crinetics Pharmaceuticals	2.1497 of 5 stars	$83.85 +0.1%	$78.27 -6.7%	+200.0%	$8.83B	$18.07M	N/A	210	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NRIX) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nurix Therapeutics (NRIX) Competitors

NRIX vs. KYMR, PRAX, SYRE, CRNX, and PTGX

How does Nurix Therapeutics compare to Kymera Therapeutics?

Summary

How does Nurix Therapeutics compare to Praxis Precision Medicines?

Summary

How does Nurix Therapeutics compare to Spyre Therapeutics?

Summary

How does Nurix Therapeutics compare to Crinetics Pharmaceuticals?

Summary

How does Nurix Therapeutics compare to Protagonist Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRIX vs. The Competition

Nurix Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nurix Therapeutics (NRIX) Competitors

NRIX vs. KYMR, PRAX, SYRE, CRNX, and PTGX

How does Nurix Therapeutics compare to Kymera Therapeutics?

Do analysts prefer NRIX or KYMR?

Is NRIX or KYMR more profitable?

Which has more risk and volatility, NRIX or KYMR?

Which has better valuation & earnings, NRIX or KYMR?

Does the media prefer NRIX or KYMR?

Summary

How does Nurix Therapeutics compare to Praxis Precision Medicines?

Is PRAX or NRIX more profitable?

Which has more volatility and risk, PRAX or NRIX?

Does the media favor PRAX or NRIX?

Do institutionals and insiders hold more shares of PRAX or NRIX?

Which has stronger valuation and earnings, PRAX or NRIX?

Do analysts recommend PRAX or NRIX?

Summary

How does Nurix Therapeutics compare to Spyre Therapeutics?

Do institutionals & insiders have more ownership in NRIX or SYRE?

Is NRIX or SYRE more profitable?

Which has higher valuation & earnings, NRIX or SYRE?

Does the media prefer NRIX or SYRE?

Do analysts prefer NRIX or SYRE?

Which has more risk and volatility, NRIX or SYRE?

Summary

How does Nurix Therapeutics compare to Crinetics Pharmaceuticals?

Which has better valuation and earnings, CRNX or NRIX?

Is CRNX or NRIX more profitable?

Do analysts recommend CRNX or NRIX?

Do institutionals and insiders believe in CRNX or NRIX?

Does the media favor CRNX or NRIX?

Which has more risk and volatility, CRNX or NRIX?

Summary

How does Nurix Therapeutics compare to Protagonist Therapeutics?

Do analysts recommend PTGX or NRIX?

Is PTGX or NRIX more profitable?

Does the media favor PTGX or NRIX?

Which has preferable valuation and earnings, PTGX or NRIX?

Do institutionals & insiders hold more shares of PTGX or NRIX?

Which has more risk & volatility, PTGX or NRIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRIX vs. The Competition

Nurix Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools